pSivida Corp

PRODUCTS / BrachySil™


BrachySil™, (32P-BioSilicon) is a novel brachytherapy product currently in development for the treatment of solid tumors. Developed from our proprietary nano-structured porous silicon, BioSilicon, BrachySil is a medical device containing beta-emitting phosphorous 32-P that is administered under a local anesthetic via direct intraturmoral injection using a fine gauge needle with ultrasound or CT guidance.

BrachySil comprises 30 micron particles of highly pure BioSilicon encapsulating radioactive phosphorous (32P) closely bonded within an internal silicon microcrystalline structure. The microparticles are designed to remain localized within the tissues and deliver a retained and targeted dose of beta radiation.

We have successfully conducted a dose ranging clinical trial in pancreatic cancer. The study was designed to determine the safety of escalating radiation doses of the BrachySil device, with tumor response as a secondary endpoint.

We also completed an initial safety study for the treatment of pancreatic cancer. Preliminary data, presented at ASCO (American Society of Clinical Oncology) in January 2008, showed disease control in 82% of patients and an overall median survival of 309 days.

Pancreatic cancer is the fourth most frequent cause of cancer death and one of the world's most aggressive cancers with an average five year survival rate of 4%. Over 80% of patients present with inoperable locally advanced or metastatic disease. The median survival for these patients following diagnosis is typically less than 178 days with standard chemotherapy. This is an area of significant unmet medical need.

pSivida has worldwide rights for the development and marketing of our BioSilicon technology and extensive intellectual property protection.